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A B S T R A C T 
Opioids are increasingly used to control chronic 
non-cancer pain globally. International opioid 
guidelines have been issued in many different 
countries but a similar document is not generally 
available in Hong Kong. Chronic opioid therapy has 
a role in multidisciplinary management of chronic 
non-cancer pain despite insufficient evidence for 
its effectiveness and safety for long-term use. This 
document reviews the current literature to inform 
Hong Kong practitioners about the rational use of 
chronic opioid therapy in chronic non-cancer pain. It 
also aims to provide useful recommendations for the 
appropriate, effective, and safe use of such therapy 
in the management of chronic non-cancer pain in 
adults. Physicians should conduct a comprehensive 
biopsychosocial evaluation of patients prior to the 
commencement of opioid therapy. When opioid use 
is deemed appropriate, the patient should provide 
informed consent within an agreement that specifies 
treatment goals and expectations. A trial of opioid 
can be commenced and, provided there is progress 
towards treatment goals, then chronic therapy 
can be considered at a dose that minimises harm. 
Monitoring of effectiveness, safety, and drug misuse 
should be continued. Treatment should be stopped 
when opioids become ineffective, intolerable, 
or misused. The driving principles for opioid 
prescription in chronic pain management should 
be: start with a low dose, titrate slowly, and maintain 
within the shortest possible time.
Opioid therapy for chronic non-cancer pain: 
guidelines for Hong Kong
Introduction
Chronic pain is pain that persists beyond the usual 
time of healing, usually marked as 6 months or even 
3 months by the International Association for the 
Study of Pain (IASP).1 Chronic pain arises from 
complex changes to central or peripheral nervous 
system signalling, or both. The perception of pain 
is modulated by an individual cognitive factors and 
the environment,2 and can significantly compromise 
daily function, resulting in an important health issue. 
Hong Kong survey data estimated the prevalence of 
chronic pain to affect 10.8% of the population in 2000 
and 35% in 2007.3,4 Survey participants with chronic 
pain from an earlier study reported a significant 
impact on their daily lives.3 Moreover, chronic pain 
placed a substantial load on productivity, with an 
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estimated loss of approximately 0.2 working days per 
person in the working population per year, and on 
health care resources, with almost three quarters of 
respondents consulting a health care practitioner. 
The latter survey found that reports of chronic pain 
were strongly associated with co-morbid mental 
health problems and anxiety.4
 Opioid therapy is accepted for acute pain 
and cancer pain,5,6 but its effectiveness and safety 
for chronic non-cancer pain (CNCP) remains 
contentious. By definition, CNCP refers to non-
malignant pain that lasts beyond the time of tissue 
healing, or longer than 3 months.1 Authors cite weak 
evidence for opioid use for CNCP due to the lack of 
randomised controlled trials with long follow-up.7,8 
Based on systematic reviews, opioids for CNCP—
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香港非癌症慢性疼痛的鴉片類藥物指引
張志偉、陳智榮、曾煥彬、朱銘知、崔俊明、何培達、 
林智穎、羅尚尉、李麗英、黃河山、黃啟宗
使用鴉片類藥物來控制非癌症慢性疼痛越趨普遍。全球多個國家已經
制定有關鴉片類藥物的使用準則，可是香港並未有類似的指引。儘管
缺乏證據支持長期使用鴉片類藥物的有效性和安全性，但在跨學科治
理非癌症慢性疼痛方面，這些藥物確能發揮作用。本文回顧有關合理
使用鴉片類藥物作非癌症慢性疼痛治療的最新文獻，為香港醫護人員
如何能適當、有效和安全地使用這類藥物在成年患者身上提供建議。
使用這種治療前，醫生應為患者作全面的生物心理社會評估。如果認
為使用鴉片類藥物作治療是恰當，應先讓患者簽署同意書列明治療的
目的和期望，然後才開始嘗試使用鴉片類藥物治療痛症。如果治療達
標，可緩慢增加劑量至對患者產生最少副作用的最佳目標劑量。治療
過程中應繼續監察藥物的效用和安全性，避免藥物濫用。假如發現鴉
片類藥物變得無效，患者未能忍受藥物不良反應或者出現藥物濫用，
便應停止治療。使用鴉片類藥物治療慢性疼痛的準則應是：訂定最低
起始劑量，再緩慢地增加劑量，以及儘可能於最短時間內維持劑量。
including neuropathic pain, nociceptive pain, and 
arthritic pain—confer some benefit by reducing 
pain intensity and improving functional outcome 
compared with placebo and other non-steroidal 
anti-inflammatory drugs,9-13 but high-quality studies 
are rare, and treatment duration is short, ranging 
from 2 weeks to 6 months. A proportion of patients 
in the studies reviewed did not progress to long-term 
therapy due to adverse effects.12 Discontinuation 
rates from adverse effects were almost 30%, with the 
most frequently reported events being constipation, 
nausea, dizziness, drowsiness, and headache.12
 The potential to develop opioid abuse or 
addiction with long-term therapy is also a concern. 
In studies reviewed, addiction or abuse rates were 
reported to range from 0.27% to 0.43%.12,14,15 Deaths 
related to opioid analgesic overdose have been 
increasing, and is being linked to an increase in opioid 
prescriptions for pain.16,17 Indeed, chronic opioid 
exposure from prescription appears to be a strong 
risk factor for an opioid misuse event in patients just 
diagnosed with CNCP.18 Other potential harm from 
chronic opioid use includes increased fracture risk,19 
androgen deficiency,20 respiratory depression,21 
cognitive impairment,22 impaired immunity,23 and 
opioid-induced hyperalgesia.24,25 
 Global consumption of opioids for moderate-
to-severe pain increased approximately 15-fold 
from 1980 to 2012.26 Generally, opioid consumption 
of countries in Asia, including Hong Kong, is low 
relative to the global picture (Fig27), but showing an 
increasing trend.27,28 Physicians in Hong Kong may be 
reluctant to prescribe opioids for long-term therapy 
due to fear of patient addiction. There may also be 
a cultural prejudice against opioid use stemming 
FIG.  Global morphine equivalence consumption (2013)27
The consumption statistics are displayed in milligrams per capita, which is calculated by dividing the total amount of opioid 
consumed in kilograms by the population of the country for that particular year (cite United Nations population data). This 
provides a population-based statistic that allows for comparisons between countries
Reproduced with permission from Pain & Policy Studies Group. Opioid consumption maps—Morphine equivalence (ME), mg/capita, 
2013
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from a history of China’s involvement in the global 
opium trade in the early part of the century.29 Other 
possible barriers to prescription and patient care 
may include inadequate physician education about 
pain management, and lack of physician-patient 
communication about the seriousness of the pain 
problem. The absence of a central registry for opioid 
prescriptions, and the limited number of addiction 
specialists are potential local logistical barriers. 
With the introduction of opioid choices in Hong 
Kong, however, the prescription of strong opioids for 
long-term treatment may become more common. 
Examples of strong opioids for CNCP used in Hong 
Kong are listed in Box 1.30 
 Guidelines governing the use of opioids for 
patients with CNCP have been issued in different 
countries according to their needs.31-38 The Hospital 
Authority has recently introduced an opioid 
guideline for CNCP for public hospital use. A similar 
guide is not readily available for physicians who are 
involved in CNCP management but practise outside 
Hospital Authority in Hong Kong. This document 
aims to serve as a resource and uniform guide for 
the appropriate, effective, and safe use of chronic 
opioid therapy (COT) in the management of CNCP 
in adults based on local considerations; COT is 
regarded as the use of strong opioids for more than 3 
months.39 This guideline provides recommendations 
about patient selection, risk screening, initiation 
of COT, and monitoring during COT, based on a 
review of the current literature. The target audience 
is all physicians, especially non-pain specialists, 
and other health care professionals involved in the 
multidisciplinary management of the patient with 
CNCP, who are considering prescribing COT. 
General considerations for using 
opioid in patients with chronic 
non-cancer pain 
The biopsychosocial model describes pain as bodily 
disruption shaped by an individual’s subjective 
perception. Biological processes, emotions, and 
social factors all influence the pain experience.2 
Consequently, chronic pain is a complex condition 
that requires a multidisciplinary approach to 
both evaluation and management, preferably in a 
coordinated treatment programme.40,41 The IASP 
recognises the effectiveness of multidisciplinary pain 
programmes for chronic pain, and recommended the 
establishment of multidisciplinary pain clinics or pain 
centres; the latter of which should be associated with 
a research or academic programme.40 Staff at both 
pain centres and clinics should include practitioners 
from various disciplines deemed expert in pain 
management. Physicians, nurses, mental health 
professionals, and physical therapists are among 
those who comprise a team that coordinates diagnosis 
and management, with constant communication, 
preferably in one setting.40,41 Essential elements of 
multidisciplinary pain programmes address pain 
management, psychosocial recovery, and physical 
rehabilitation, and include medication, physical 
therapy, and cognitive and behavioural strategies.42 
Such programmes have been proven clinically 
effective and cost-effective.43-45 
 In fact, COT is just part of the multimodal 
strategy to manage CNCP. Experts do not 
recommend opioids for first-line treatment of 
CNCP.34,36,38 Non-opioid treatment options, both 
non-pharmacological and pharmacological (eg 
typical analgesics), should be tried first. Despite 
limited evidence to support the safe and effective 
use of opioids in CNCP, they may be considered 
for selected patients who have moderate-to-severe 
pain and who have not responded adequately 
to non-opioid therapy.38 In accordance with 
the biopsychosocial model, treatment of CNCP 
should address the physical, psychological, and 
social aspects of the pain problem.41 Treatment 
of CNCP should thus aim to reduce pain and 
support patients’ physical, psychological, social, 
and work functioning.40 The goals of COT include 
pain reduction, reduction of pain-associated 
symptoms such as anxiety and sleep problems, 
and improvement of daily function.46,47 These goals 
should be individualised and utilise achievable 
milestones without excessive use of opioids.46 Indeed, 
daily function outcomes were deemed important by 
survey participants with chronic pain,48 and should 
be targets for improvement along with pain control 
(Box 2). 
Recommendations 
•	 Chronic	opioid	therapy	should	be	considered	only	
as part of a multidisciplinary pain management 
Buprenorphine
Fentanyl
Methadone
Morphine
Oxycodone
Pain control
Restoration of functional status and activities of daily life
Enhanced self-management, reduced use of other health 
care resources
Return to work
Improved family and social interactions
Improved sleep and psychological wellbeing
Improved overall quality of life
BOX 1.  Strong opioids registered in Hong Kong for chronic 
pain management30
BOX 2.  Goals of chronic opioid therapy
#  Opioids for chronic non-cancer pain  # 
499Hong Kong Med J  ⎥  Volume 22 Number 5  ⎥  October 2016  ⎥  www.hkmj.org
strategy. 
•	 Opioids	 should	 be	 prescribed	 only	 after	
exhausting other pharmacological and non-
pharmacological treatment options.
•	 Treatment	 goals	 acceptable	 to	 both	 patients	
and their physicians should be set when COT is 
considered. 
•	 When	prescribed,	COT	should	aim	to	reasonably	
reduce pain and its associated symptoms, as well 
as improve functional outcomes. 
Patient evaluation and selection
Prior to starting COT, a comprehensive patient 
evaluation should be carried out to form a diagnosis, 
establish the cause of pain, describe pain intensity, 
and determine a patient’s risk profile with the 
use of opioids.38,46 The evaluation informs on the 
suitability of a patient for COT, and, if the decision 
to pursue COT is made, provides the foundation 
for individualising a treatment plan. A thorough 
history and physical examination with appropriate 
investigations are essential. The pain complaint 
should be thoroughly investigated with regard to 
characteristics, underlying factors, and effects on the 
patient’s functional status.38,46 Assessment should 
include a medical and psychosocial history, including 
previous medication, general health, family support, 
and work status. For example, increased use of 
opioids for pain control prior to spine surgery was 
found to be associated with worse postoperative 
outcomes, such as increased demand for opioids 
after surgery, and decreased incidence of opioid 
independence 1 year after surgery.49,50 This highlights 
the need for a complete evaluation and screening of 
each patient prior to opioid use. Evaluation findings 
may impact subsequent patient counselling and 
treatment planning. 
 The rate of problematic opioid use or aberrant 
drug–related behaviour in patients with CNCP on 
COT is 11.5%.51 Prevalence of substance use disorder 
among patients with CNCP, with or without opioid 
use, ranges from 3% to 48%.52 Because problematic 
opioid use complicates pain treatment and may 
cause significant harm, a patient’s risk for opioid 
abuse, misuse, or addiction must be assessed prior 
to COT.38,46,53,54 Screening helps the physician to 
anticipate the patient’s risk of developing aberrant 
behaviour while on COT.53,54 Family and personal 
history of substance abuse, a history of psychiatric 
or mood disorders, and younger age have not been 
validated as predictive of opioid misuse, but have 
been shown to potentially increase risk.52,55,56 
 The physician can utilise structured clinical 
interviews and self-reports to elicit these factors.52,56 
Questionnaires such as the Opioid Risk Tool, which 
assigns weights to predictive factors of opioid misuse, 
may be useful.57 The presence of apparent predictors 
of misuse such as a personal or family history of 
substance abuse or addiction does not necessarily 
preclude the use of opioids, but may affect structure 
of therapy (eg closer monitoring, stricter prescription 
practice) and require additional consultation from 
specialists, including psychiatrists.54 Urine drug 
screening (UDS) may be a useful aid in detection 
of latent drug abuse. Every assessment must be 
thoroughly documented.
 According to addiction specialists from the 
Hong Kong College of Psychiatrists, screening by 
psychiatrists for suitability of high-risk patients 
for COT may not be useful, as evidence to support 
reduced substance abuse risk through conjoint 
selection by pain specialists and psychiatrists is 
lacking. There is also inadequate evidence that the 
future risk of opioid abuse is reduced by treating 
substance abuse prior to COT; thus, the decision to 
make this treatment a prerequisite for COT rests on 
the pain management team (written communication, 
Clinical Division of Substance Abuse & Addiction 
Psychiatry, Hong Kong College of Psychiatrists, 
2016). Patients with active substance abuse (opioid, 
non-opioid, or both) and psychological disturbances 
may be referred to substance abuse clinics (SACs) 
in Hong Kong for pre-COT psychiatric treatment 
(Appendix 1). 
Recommendations
•	 Patients	 considered	 for	 COT	 should	 have	 a	
thorough physical, psychological, and social 
assessment.
•	 Risk	of	substance	misuse	or	addiction	should	also	
be assessed for appropriate treatment planning. 
Prescription of chronic opioids
Informed consent and documentation
Guides on COT for CNCP recognise the need for 
informed consent to explain the benefits, risks, 
and complications of COT before a trial of opioid 
therapy, and when the decision to use COT is 
reached.38,46 Consent in the form of a written plan 
or treatment agreement, or opioid contract, can 
set expectations between the physician and patient 
regarding their actions and treatment targets.13,38,46 
The usefulness of a contract in promoting adherence 
to a COT regimen lacks evidence, however. Also, 
use of a contract has underlying ethical issues 
relating to patient autonomy and the assumption of 
potential opioid abuse.13,58 Nevertheless, if utilised, 
an agreement should outline information on COT 
and alternative treatment options, benefits, risks 
(which include adverse effects, behavioural risks, 
and medical complications), steps to reach treatment 
goals, means of monitoring improvements, and 
conditions for continuing or discontinuing therapy 
(Appendix 2).13,38,58 Specifically, it may include 
from whom and where the patients should obtain 
  #  Cheung et al #
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their prescription, the number and time of office 
follow-ups, and expectations on use of UDS.46,58 The 
agreement should be reviewed continually during 
treatment.46
Trial of opioid therapy
An opioid trial assesses patients’ responsiveness 
to opioids. Dose titration during an opioid trial 
determines the lowest effective dose with the least 
or minimal side-effects for an individually tailored 
programme.59 The choice of opioid should be based 
on factors related to the individual patient, such as 
previous response to opioids, health status, treatment 
goals, predicted risks; on medication-related factors, 
such as availability and pharmacological and adverse 
effect profiles; and on physician experience and 
expertise.33,36,59 Parenteral forms of opioids are not 
recommended for an opioid trial due to risk of 
abuse.33,36 
 Opioids should be titrated slowly, for example, 
at increments of 10 to 50 mg equivalent per day 
of a long-acting opioid, until the optimal dose 
that provides benefit with the least side-effects is 
attained.33,47,60 The optimal dose is suggested to lead 
to a 30% pain reduction (based on an 11-point scale) 
that does not cause significant adverse effects.33,61 A 
trial of therapy may last weeks or months. Duration 
can be set from 4 to 6 weeks, or up to 90 days in some 
pain centres.46,47,60 The target results and duration of 
the trial period should be understood and agreed by 
the patient.46,60 
Prescription for special concerns
Driving and work safety are potential concerns when 
COT is used. Studies have not shown impairment 
of driving-related activities with opioids,13,62,63 but 
patients should be informed of factors related to 
opioid use that may cause impairment, including 
initiating opioids or changing opioid dose, poor 
sleep, severe pain, and concomitant intake of 
alcohol or sedating medications.13,33,38 Patients 
should be advised to avoid driving or participating 
in potentially dangerous activities if they show signs 
of impaired cognition or psychomotor ability, such 
as somnolence, poor coordination, or decreased 
concentration.33,38
 Pregnant patients or patients planning to get 
pregnant should be counselled on the risks of COT 
during pregnancy. Such therapy during pregnancy 
has been found to be associated with neonatal 
withdrawal syndrome, poor birth outcome, and 
certain birth defects.64-66 Because of this, COT during 
pregnancy is not encouraged unless the potential 
benefits outweigh the risks.38,47 
Recommendations
•	 Informed	consent	should	be	obtained	before	an	
opioid trial as well as before the start of COT. 
•	 Prior	to	COT,	an	opioid	trial	should	be	conducted	
to assess patient response and to determine an 
optimal opioid dose.
•	 The	 choice	 of	 drugs	 and	 initial	 dosing	 should	
be individualised according to the drug profile, 
patient characteristics and goals, and physician 
experience. 
•	 Patients	on	opioids	who	show	signs	of	impaired	
cognition or psychomotor activity should be 
cautioned against driving and other potentially 
dangerous activities. 
•	 Use	 of	 COT	 during	 pregnancy	 is	 discouraged	
because opioids may lead to poor birth outcomes. 
Monitoring during chronic opioid 
therapy
Ongoing assessment and regular monitoring during 
COT allows physicians to characterise patients who 
continue to benefit from opioids or who may need 
changes in their treatment programme. During 
an opioid trial, the patient is regularly monitored, 
usually at weekly intervals, to assess the four A’s: 
analgesia, activity, adverse effects, and aberrant 
behaviour.33,60,67 The dose is adjusted based on 
changes in pain intensity, improvements in daily 
function, and development of side-effects and of 
aberrant behaviour.33,35,46 Validated pain assessment 
tools such as the Brief Pain Inventory or the Pain, 
Enjoyment, and General Activity scale may be used 
at baseline and at regular intervals thereafter to 
describe changes in pain relief and function.33,46,47 
Drug-related behaviour can be monitored through 
patient interviews, observation, and UDS. 
 Evidence is lacking on the reliability of UDS in 
predicting aberrant behaviour, and UDS still needs 
to be evaluated if it improves clinical outcomes.37 
Nonetheless, UDS provides important information 
on adherence to the treatment plan and existence 
of possible drug misuse when appropriately used 
with other monitoring tools. Although other 
biological specimens may be tested, obtaining 
urine is considered practical and convenient, and 
results can be obtained within a few days to allow 
modification of patient care.68 Physicians should 
be aware of limitations in interpreting results 
and should maintain communication with testing 
laboratories to resolve any doubts.68 In addition, 
differential diagnoses for each result should be 
considered, for example, absence of prescribed drug 
in the urine could indicate non-access to required 
prescription, or diversion of the prescription.37,69 
These considerations should facilitate a discussion 
with the patient in order to improve care. Prior to 
the onset of opioid therapy, it is important to educate 
the patient and specify the objectives of UDS in the 
treatment agreement to avoid confrontation and 
uphold a strong physician-patient relationship.69 
 There is no agreement on the frequency of 
#  Opioids for chronic non-cancer pain  # 
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UDS, but it should be performed as frequently as 
necessary according to the patient’s risk for misuse, 
occurrence of aberrant behaviour, and on availability 
of the test.37,47 If aberrant drug behaviour is noticed, 
the patient may need more intensive monitoring and 
referral to a pain or substance abuse specialist.47,60 
Continuation of opioid therapy may be agreed 
upon by physician and patient if there is note of 
progress towards the patient’s goals as determined 
from regular monitoring.60 If the patient is deemed 
suitable to continue opioids in the long term after an 
opioid trial has established a stable dose, monitoring 
of the four A’s is undertaken at regular intervals.60 
Intervals can be as far apart as 6 months for patients 
with no risk issues, or as frequent as monthly for 
those at risk of opioid misuse, or those taking doses 
near the threshold level.47 
Recommendations
•	 Monitoring	 during	 COT	 should	 include	
documentation of pain intensity, level of 
functioning, presence of adverse events, and 
adherence to prescribed therapies.
•	 Validated	 pain	 assessment	 tools	 may	 be	 used	
at baseline and regularly thereafter to describe 
changes in pain and function.
Opioid rotation 
Patients who initially responded but have become 
tolerant despite escalating doses, and those in whom 
side-effects limit dose increases, may consider 
an opioid switch or rotation.70 Despite the lack of 
evidence from controlled studies for the clinical 
effectiveness of opioid rotation,71,72 the strategy may 
be useful based on observed differences in individual 
responses to various opioids.73 This occurrence 
may be explained by genetic variations in receptor 
subtypes that modulate drug effects, and that also 
potentially promote incomplete cross-tolerance 
among opioids.74 
 Opioid rotation involves selection of a new 
opioid, determination of its appropriate initial dose, 
and subsequent titration for a satisfactory balance of 
efficacy and side-effects.70 Use of an equianalgesic 
table can facilitate estimation of the new drug’s 
initial dose.33,75-78 Its dose should approximate the 
dose of the previous drug (Table 133,75-78). Drug 
potencies reflected by the reference table may be 
underestimated74; therefore, experts support an initial 
automatic reduction in the estimated equianalgesic 
dose of the new drug by 25% to 50% for safety.70 If the 
previous dose was high, a reduction by at least 50% is 
recommended by some authors.33 Exceptions to this 
include a switch to methadone, which should use a 
reduction of 75% to 90%, and switch to transdermal 
fentanyl, which does not require a reduction.70 This 
initial computation should be adjusted or retained 
based on the patient’s clinical situation. Subsequent 
drug titration should be based on this initial dose.70 
TABLE 1.  Conversion factors for equianalgesic dose of selected opioids33,75-78 *
Australia75 United Kingdom76 United States77 Canada33 Europe78
Oral preparations
Swallowed
Morphine (mg/day) 1 NL 1 1 1
Oxycodone (mg/day) 1.5 1.5-2 1-2 1.5 1.5
Hydromorphone (mg/day) 5 3.5-10 4 5 NL
Codeine (mg/day) 0.13 0.08-0.1 NL 0.15 NL
Dextropropoxyphene (mg/day) 0.1 NL NL NL NL
Tramadol (mg/day) 0.2 0.1-0.17 NL NL NL
Tapentadol (mg/day) 0.4 0.3-0.8 NL NL NL
Methadone (mg/day) 4.7 NL NL NL NL
Buccal/sublingual
Buprenorphine (mg/day) 37.5 80 NL NL NL
Fentanyl (µg/day) 0.1 NL NL NL NL
Sufentanil (µg/day) 0.5 NL NL NL NL
Transdermal preparations
Buprenorphine (µg/h) 2.5 NL NL NL 1.7
Fentanyl (µg/h) 3 NL NL NL 2.4
Abbreviation: NL = value not listed in reference
* Value as listed in the reference
  #  Cheung et al #
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Recommendations
•	 When	 switching	 to	 a	 new	 opioid,	 calculate	 the	
equianalgesic dose using a reference equianal-
gesic table. 
•	 Reduction	of	the	calculated	dose	is	recommended	
for safety. 
•	 Prior	 to	 a	 new	 opioid	 trial,	 adjust	 the	 dose	
further after reassessment of the patient’s clinical 
situation. 
Management of side-effects and 
problematic opioid use
Constipation, nausea, headache, and sedation are 
the most frequently reported opioid side-effects 
in clinical trials.12 Many side-effects reportedly 
diminish over time,12 but some side-effects such as 
constipation and vomiting may be severe enough to 
prompt discontinuation from trials. Constipation, in 
particular, may not diminish and cause significant 
severe discomfort.79 Opioid dose adjustment, opioid 
rotation, and proactive therapy (eg stool softeners 
for constipation) are strategies that can minimise 
severity of adverse effects.21,79 Common opioid-
associated side-effects should be anticipated and 
managed appropriately when identified to maintain 
compliance (Table 2).33
 Problematic drug use or aberrant drug 
behaviour may arise from opioid use. As described 
previously, patients on COT who are at high 
risk of opioid misuse or addiction may need 
additional consultation with addiction experts, 
and a restructuring of their programme to include 
frequent, close monitoring.33,46,47,54 In addition 
to patient interviews, proper drug use may be 
monitored through methods such as regular visits, 
pill counts, and UDS.80 Physicians should attempt 
to identify the cause of behaviour that suggests 
the possibility of opioid misuse. It is important to 
be aware of pseudo-addiction, which apparently 
exhibits the same compulsive behaviours for opioids 
as in addiction, but is due to inadequate pain relief 
from undermedication.81 
 When drug misuse is identified, the patient 
should undergo a complete re-evaluation for 
treatment modification.33 Repeated, serious 
aberrant behaviour requires discontinuation of 
COT and referral to substance abuse specialists 
for detoxification.33,47 Referral channels and 
treatment through SACs for patients with significant 
psychological disturbance or addiction features (eg 
aberrant drug behaviour, other substance abuse such 
as benzodiazepines) are available in Hong Kong 
(Appendix 1). 
Recommendations
•	 Anticipate	 common	 side-effects	 and	 manage	
appropriately.
•	 If	problematic	drug	use	is	recognised,	re-evaluate	
the patient and modify treatment.
•	 Discontinue	 COT	 if	 aberrant	 behaviour	 is	
present. Referral to substance abuse specialists is 
warranted. 
Upper dose limit and exit strategy
The goals of COT should be revisited at regular 
intervals to see if patients can meet their targets 
within a defined dose range, determined from the 
initial daily dose titrated to the lowest effective dose. 
It is recommended that the upper dose titration 
limit should not exceed 120 mg of oral morphine or 
its equivalent, or 200 mg in some centres.33,38,47,60 If 
the daily dose exceeds this limit, a reassessment of 
the pain condition, potential for misuse, and need 
for more frequent monitoring is warranted.33,38 
Indications for discontinuation include no change or 
improvement in therapeutic goals despite escalating 
doses, intolerance to side-effects, and persistence of 
aberrant behaviour. If the decision to discontinue 
opioids is reached, the opioid should be tapered to 
avoid withdrawal problems.33,46,47,60 
 The tapering plan is variable, but generally, a 
reduction of 10% per week from the original dose 
is well tolerated.33,47,60 A faster or slower rate may 
be suitable depending on the patient’s situation. 
Physicians should monitor patients for changes 
in pain and for the appearance of side-effects, 
withdrawal symptoms, and behavioural issues. These 
concerns should be properly managed. In some 
cases, a referral to the appropriate specialists may 
be warranted. Likewise, patients who fail to benefit 
from COT and who need discontinuation may be 
referred to SACs in Hong Kong for detoxification 
and rehabilitation services (written communication, 
Clinical Division of Substance Abuse & Addiction 
Psychiatry, Hong Kong College of Psychiatrists, 
2016).
TABLE 2.  Opioid-associated side-effects and complications33
Common side-effects Long-term complications Specific drug effects
Constipation, nausea, vomiting, 
drowsiness, dizziness, sedation, dry 
mouth, dry skin, pruritus, respiratory 
depression
Constipation, physical dependence, tolerance, 
addiction, opioid-induced hyperalgesia, cognitive 
dysfunction, impaired immunity, reduced sexual 
function and infertility
Methadone can produce prolonged QT interval 
corrected for heart rate
Hydrocodone may cause sensorineural hearing loss
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Recommendations
•	 Chronic	 opioid	 therapy	 should	 be	 stopped	
if patients experience no progress towards 
treatment goals, experience intolerable side-
effects, or are engaged in repeated aberrant drug-
related behaviours. 
•	 Opioids	should	be	tapered	to	avoid	withdrawal.
Conclusion
Strong opioids play a role in the multimodal 
management of CNCP. They may be appropriate 
for selected patients despite insufficient evidence 
of effectiveness. Opioid therapy is potentially 
associated with common side-effects and significant 
harm; thus, careful patient selection by a thorough 
patient evaluation prior to treatment, and careful 
dose titration and monitoring during initiation and 
long-term therapy, are all recommended steps for 
rational opioid use in CNCP. Whenever opioid is 
prescribed for chronic pain management, it should 
be started with a low dose and titrated slowly, as well 
as maintained for the shortest possible time. 
Appendices
Additional material related to this article can be 
found on the HKMJ website. Please go to <http://
www.hkmj.org>, and search for the article.
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